Roche Holding AG Part. Cert.

Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
  • TickerROG
  • ISINCH0012032048
  • ExchangeSix Swiss Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySwitzerland

Analysts

Eric Le Berrigaud

ROCHE: PharmaDay 2019: not transformative, but aimed at sharing confidence in the pipeline | BUY - Top Picks | CHF340(+25%)

ROCHE - BUY - Top Picks | CHF340(+25%) PharmaDay 2019: not transformative, but aimed at sharing confidence in the pipeline Behind images from the outside, a profound change in practices Roche wants to remain a long-term play A rich agenda over the next 18 months We are introducing satralizumab to our sales model

Alfred Glaser ...
  • Charles Lepetitpas
  • Delphine Brault
  • François Maury
  • Georges Dieng
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/17/2019

At the road show that we organised in Paris, Eiffage’s management seemed particularly reassuring about the operating momentum (contracting volumes, trends in margins and motorway traffic) and its external growth strategy. We share this confidence and reiterate our Buy recommendation with a target price raised to € 110 (vs € 103). - Cf. equity report published this morning. - ...

Alfred Glaser ...
  • Charles Lepetitpas
  • Delphine Brault
  • François Maury
  • Georges Dieng
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 17/09/2019

Lors du roadshow que nous avons organisé à Paris, le management d’Eiffage s’est montré particulièrement rassurant tant sur la dynamique opérationnelle (volumes de travaux, évolution des marges, trafic autoroutier) que sur sa stratégie de croissance externe. Nous partageons cette confiance et réitérons notre recommandation Achat avec un objectif de cours relevé à 110 € (vs 103 €). Cf. étude publiée ce jour. - ...

Martial Descoutures ...
  • Oussema Denguir

Roche Holding : Pressure in the short term but an ambitious revival

>The timing of the revival will be key - Yesterday Roche hosted an investors’ day which primarily focused on its pharma franchise. In our view, this presentation had two main aims: i/ to reassure the market on the group’s capacity to more than offset the arrival of biosimilars Avastin, Herceptin and Mabthera, but also ii) to demonstrate the undervaluation of its pipeline (early and late stage). One of the key points of this presentation was management’s view on t...

Martial Descoutures ...
  • Oussema Denguir

Roche Holding : Une pression CT mais un renouvellement ambitieux

>Un timing de renouvellement qui sera la clé - Hier se tenait la journée Investisseurs de Roche ciblant essentiellement sa franchise Pharma. Nous voyons deux objectifs à cette présentation : i) rassurer les marchés sur la capacité du groupe à plus que compenser l’entrée des biosimilaires d’Avastin, Herceptin et Mabthera mais aussi ii) démontrer une sous-valorisation de son pipeline (early et late stage). Un des points clés de la présentation était la perception d...

Jean-Jacques Le Fur

Roche: Positive OS for Tecentriq in ES-SCLC (IMpower 133) after the disappointment in NSCLC

Brief Comment - Roche: (NEUTRAL, Fair Value CHF266 (+14%)) Positive OS for Tecentriq in ES-SCLC (IMpower 133) after the disappointment in NSCLC

Roche Holding AG - June 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Roche Holding AG: Update to credit analysis

Our credit view of Roche Holding AG, reflecting its ongoing strong financial performance as its patent cliff will intensify.

Roche Holding AG - December 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Roche Holding AG: $4.8 billion acquisition of Spark will have limited impact on credit metrics, but does not come without risks

Credit implications of Roche's acquisition of Spark Therapeutics

Roche Holding AG: Update to credit analysis

Our credit view of Roche Holding AG, reflecting its very strong financial profile, driven by sales growth from new products, which will offset a large upcoming patent cliff.

Eric Le Berrigaud

ROCHE: PharmaDay 2019: not transformative, but aimed at sharing confidence in the pipeline | BUY - Top Picks | CHF340(+25%)

ROCHE - BUY - Top Picks | CHF340(+25%) PharmaDay 2019: not transformative, but aimed at sharing confidence in the pipeline Behind images from the outside, a profound change in practices Roche wants to remain a long-term play A rich agenda over the next 18 months We are introducing satralizumab to our sales model

Martial Descoutures ...
  • Oussema Denguir

Roche Holding : Pressure in the short term but an ambitious revival

>The timing of the revival will be key - Yesterday Roche hosted an investors’ day which primarily focused on its pharma franchise. In our view, this presentation had two main aims: i/ to reassure the market on the group’s capacity to more than offset the arrival of biosimilars Avastin, Herceptin and Mabthera, but also ii) to demonstrate the undervaluation of its pipeline (early and late stage). One of the key points of this presentation was management’s view on t...

Martial Descoutures ...
  • Oussema Denguir

Roche Holding : Une pression CT mais un renouvellement ambitieux

>Un timing de renouvellement qui sera la clé - Hier se tenait la journée Investisseurs de Roche ciblant essentiellement sa franchise Pharma. Nous voyons deux objectifs à cette présentation : i) rassurer les marchés sur la capacité du groupe à plus que compenser l’entrée des biosimilaires d’Avastin, Herceptin et Mabthera mais aussi ii) démontrer une sous-valorisation de son pipeline (early et late stage). Un des points clés de la présentation était la perception d...

Eric Le Berrigaud

ROCHE: Two more clinical successes announced | BUY - Top Picks | CHF340(+25%)

ROCHE - BUY - Top Picks | CHF340(+25%) Two more clinical successes announced Two positive trial read-outs are made this morning Tecentriq works in monotherapy in 1L PD-L1 high NSCLC patients Satralizumab is now ready to be filed A PharmaDay next Monday to be held in London

Team Pharma

ODDO : Dans un contexte volatil, nous privilégions AstraZeneca et Novartis

Depuis notre étude du 6 mai dernier « favoriser l’innovation et le recentrage Pharma », le Stoxx 600 Healthcare a progressé de 8.7% vs -0.4% pour le Stoxx 600. Cette performance est notamment expliquée par des publications du S1 de bonne facture. Cependant tributaire des annonces de reformes potentielles de la santé américaine, nous considérons toujours que le secteur devrait rester volatil dans ces prochains mois. Nous maintenons dans ce contexte notre préférence pour AstraZenec...

Alfred Glaser ...
  • Charles Lepetitpas
  • Delphine Brault
  • François Maury
  • Georges Dieng
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/17/2019

At the road show that we organised in Paris, Eiffage’s management seemed particularly reassuring about the operating momentum (contracting volumes, trends in margins and motorway traffic) and its external growth strategy. We share this confidence and reiterate our Buy recommendation with a target price raised to € 110 (vs € 103). - Cf. equity report published this morning. - ...

Alfred Glaser ...
  • Charles Lepetitpas
  • Delphine Brault
  • François Maury
  • Georges Dieng
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 17/09/2019

Lors du roadshow que nous avons organisé à Paris, le management d’Eiffage s’est montré particulièrement rassurant tant sur la dynamique opérationnelle (volumes de travaux, évolution des marges, trafic autoroutier) que sur sa stratégie de croissance externe. Nous partageons cette confiance et réitérons notre recommandation Achat avec un objectif de cours relevé à 110 € (vs 103 €). Cf. étude publiée ce jour. - ...

Ahmed Ben Salem ...
  • Alain William
  • Alexandre Iatrides
  • Alfred Glaser
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emira Sagaama
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Johanna Jourdain
  • Laurence Hofmann
  • Louis Boujard
  • Manuel Martin
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Tegner
  • Pierre Corby
  • Roland Pfaender
  • Stephane Houri

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/07/2019

...

François Maury ...
  • Georges Dieng
  • Team Pharma

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/28/2019

...

François Maury ...
  • Georges Dieng
  • Team Pharma

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/06/2019

...

Nurhayati Wan

Roche Holdings

Nurhayati Wan

Roche Holdings

With a more favourable environment, ROCHE HOLDING AG improves to Positive

ROCHE HOLDING AG (CH), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date June 21, 2019, the closing price was CHF 277.15 and its potential was estimated at CHF 291.01.

Nurhayati Wan

Roche Holdings

Nurhayati Wan

Roche Holdings

Eric Le Berrigaud

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC At our Annual Oncology Day this year, two KOLs (i) summarized the key learnings from ASCO 2019 and (ii) focused specifically on the advances in lung cancer. Then, out of the five companies presenting, three did so in plenary sessions, and we report here the main messages they conveyed

Eric Le Berrigaud

ROCHE: “We are fine with the show-me mode investors are imposing us” (CFO) - Feedback | BUY - Top Picks | CHF329(+25%)

ROCHE - BUY - Top Picks | CHF329(+25%) “We are fine with the show-me mode investors are imposing us” (CFO) - Feedback 2019 is PoC for management's high degree of reliability 2020 does not look worse (at all) Upside beyond 2020 Where the consensus stands makes no nsense

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur
  • Ross Blair
  • Victor Floc’h

Healthcare: Top Picks Q2 2019: Alcon, Innate, Ipsen and Roche

Healthcare Top Picks Q2 2019: Alcon, Innate, Ipsen and Roche Looking back to Q1 2019 What to expect for Q2 2019

Eric Le Berrigaud

Pharmaceuticals | ESMO 2018: Sequencing Was the Key Word

We synthesise here the main take-away messages from the annual ESMO congress which took place in Munich in October. We present the conclusions in sections organised by organ with three main parts: renal-cell carcinoma (RCC), breast cancer (BC) and lung cancer (NSCLC) with non-uniform levels of innovation and progress. The last section is dedicated to head & neck cancer with encouraging updated data on monatuximab/cetuxima

Roche Holding – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Roche - March, 05th 2019

ITEMS 2.1, 2.2, 7 and 8 - Binding votes on the remuneration of the board of directors  and the executive management. Ethos has the following concerns over the amounts requested:  The annual bonuses that will effectively be paid out to the chairman and the CEO are significantly higher than the amounts requested at the general meeting. The remuneration of the non-executive chairman is significantly higher than that of the peer group and includes an annual bonus. For the executive management, the remuneration is significantly higher than that of the peer group and the remuneration structure is n...

Valérie GASTALDY

Analyse court terme - ROCHE HOLDING AG : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 243,70 CHF. La rupture du support à 206,50 CHF invaliderait cette tendance.

Valérie GASTALDY

Short term view - ROCHE HOLDING AG : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at CHF 243.70. Breaking below the support at CHF 206.50 would invalidate the trend.

Valérie GASTALDY

Analyse court terme - ROCHE HOLDING AG : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 243,70 CHF. La rupture du support à 206,50 CHF invaliderait cette tendance.

Valérie GASTALDY

Short term view - ROCHE HOLDING AG : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at CHF 243.70. Breaking below the support at CHF 206.50 would invalidate the trend.

Valérie GASTALDY

Medium term view - ROCHE HOLDING AG : The recent fall is getting more vigorous.

The trend is bullish. The recent fall is getting more vigorous. The next support is at CHF 203.60. A break below CHF 203.60 would challenge the trend.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch